Evidence map›Paper›PMID 31352819›Full record

ReviewHypertension (Dallas, Tex. : 1979)2019

Noncoding RNAs in Hypertension.

Amela Jusic, Yvan Devaux, EU-CardioRNA COST Action (CA17129)

Abstract readReview
In one paragraph

Review in Hypertension (Dallas, Tex. : 1979), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed.

  1. Trial
  2. Trial
  3. In-depth analysis of retinal RNA transcriptome sequencing in a rat model of hypertensive retinopathy.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. The role of miR-155 in cardiovascular diseases: Potential diagnostic and therapeutic targets.International journal of cardiology. Cardiovascular risk and prevention · 2025
    Review
  11. microRNA and Hypertension.Hypertension (Dallas, Tex. : 1979) · 2025
    Review
  12. Article
  13. MicroRNAs as Biomarkers for Metabolic Disorders in Polycystic Ovary Syndrome (PCOS): A Review.Medical science monitor : international medical journal of experimental and clinical research · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. MicroRNA-181 in cardiovascular disease: Emerging biomarkers and therapeutic targets.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Review
  19. Epigenetics as a target to mitigate excess stroke risk in people of African ancestry: A scoping review.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2024
    Article
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amela JusicFrom the Department of Biology, Faculty of Natural Sciences and Mathematics, University of Tuzla, Bosnia and Herzegovina (A.J.).
Yvan DevauxCardiovascular Research Unit, Luxembourg Institute of Health (Y.D.).
EU-CardioRNA COST Action (CA17129)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Public HealthAnimalsGene Expression RegulationHumansHypertensionHypertension, PulmonaryMicroRNAsPrevalenceReal-Time Polymerase Chain ReactionRisk AssessmentRNA, Long NoncodingSeverity of Illness IndexSignal TransductionMicroRNAsRNA, Long Noncoding

Identifiers

PMID31352819
PMCPMC6686966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.